Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS5001 in Advanced Solid Tumors and Lymphomas
NCT05279300Phase 1Suspended
- Sponsor
- CStone Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of CS5001 in solid tumor and lymphoma (2 arms), sponsored by CStone Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 6 months, Recommended Phase 2 Dose at 6 months and 2 more. Started Mar 2022; status: suspended.
02
Drugs
CS5001
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05279300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279300.